Polyspecific snake antivenom may help in antivenom crisis
Fecha
2003-02Autor
Laing, Gavin D.
Harrison, Robert A.
Theakston, R. David G.
Renjifo, J.M.
Nasidi, Abdulsalami
Gutiérrez, José María
Warrell, David A.
Metadatos
Mostrar el registro completo del ítemResumen
In Africa snakebites cause thousands of deaths annually and much permanent physical disability, but the supply of antivenom, the only specific treatment, is threatened by commercial pressures and privatisation. This has been caused over the past few years by the cessation of antivenom manufacture by Behringwerke in Germany, greatly reduced production by Aventis Pasteur in France, and the threat to continued production by Africa's sole remaining producer, the African Health Laboratory Service in Johannesburg.
External link to the item
10.1136/bmj.326.7386.447/a
Carta al editor
Colecciones
- Microbiología [1170]